ROS1 and non-small cell lung carcinoma: However, the incidence of these alterations in NSCLCs is relatively low (ALK, 3-7%; ROS1, 1-2%; c-MET, 0.8-4%) 4-6, and the majority of NSCLC patients are primarily resistant to treatment with crizotinib 7.